November 25, 2026

**BSE Limited** **Code: 532321**
P J Towers,
Dalal Street,
Mumbai-400001

**National Stock Exchange of India Limited** **Code: Zyduslife**
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 25, 2026, titled **"Zydus receives EIR from the USFDA for its API Unit – 2 manufacturing plant at Ankleshwar"**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.25 14:48:53 +05'30'

**Dhaval N. Soni**
**Company Secretary and Compliance Officer**
**Membership No. FCS7063**

**Encl.:** As above

**Zydus receives EIR from the USFDA for its API Unit – 2 manufacturing plant at Ankleshwar**

*Ahmedabad, India, 25 November, 2026*

We wish to inform that the company has received EIR from the USFDA for its API Unit – 2 manufacturing plant at Ankleshwar. The inspection was conducted from 19th to 23rd January, 2026.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

***

PRESS RELEASE

For further information please contact :
**The Corporate Communications Department**

**Zydus Lifesciences Limited**
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878